Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Company Description (as filed with the SEC)
Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma, or MM, and two partnered cancer drugs, selumetinib, partnered with AstraZeneca, and binimetinib (MEK162), partnered with Novartis. Our most advanced wholly-owned clinical stage drugs include: Proprietary Program Indication Clinical Status 1. Filanesib Kinesin spindle protein, or KSP, inhibitor for MM Phase 2 2. ARRY-797 p38 inhibitor for Lamin A/C-related dilated Phase 2 cardiomyopathy, or LMNA-DCM 3. ... More ...
Where does ARRY fit in the risk graph?
|Annual EPS Est:||$-0.69|
|Quarterly EPS Est:||-0.16|